768 related articles for article (PubMed ID: 25588354)
1. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.
Allen Reish HE; Standaert DG
J Parkinsons Dis; 2015; 5(1):1-19. PubMed ID: 25588354
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
3. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
4. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
5. Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.
Roodveldt C; Labrador-Garrido A; Gonzalez-Rey E; Fernandez-Montesinos R; Caro M; Lachaud CC; Waudby CA; Delgado M; Dobson CM; Pozo D
PLoS One; 2010 Oct; 5(10):e13481. PubMed ID: 21048992
[TBL] [Abstract][Full Text] [Related]
6. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
8. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
9. Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease.
Cardinale A; Calabrese V; de Iure A; Picconi B
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204581
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
11. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.
Kim KS; Choi YR; Park JY; Lee JH; Kim DK; Lee SJ; Paik SR; Jou I; Park SM
J Biol Chem; 2012 Jul; 287(30):24862-72. PubMed ID: 22619171
[TBL] [Abstract][Full Text] [Related]
13. Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease.
Garcia P; Jürgens-Wemheuer W; Uriarte Huarte O; Michelucci A; Masuch A; Brioschi S; Weihofen A; Koncina E; Coowar D; Heurtaux T; Glaab E; Balling R; Sousa C; Kaoma T; Nicot N; Pfander T; Schulz-Schaeffer W; Allouche A; Fischer N; Biber K; Kleine-Borgmann F; Mittelbronn M; Ostaszewski M; Schmit KJ; Buttini M
Glia; 2022 May; 70(5):935-960. PubMed ID: 35092321
[TBL] [Abstract][Full Text] [Related]
14. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.
Theodore S; Cao S; McLean PJ; Standaert DG
J Neuropathol Exp Neurol; 2008 Dec; 67(12):1149-58. PubMed ID: 19018246
[TBL] [Abstract][Full Text] [Related]
15. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
16. Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.
Thome AD; Standaert DG; Harms AS
PLoS One; 2015; 10(10):e0140566. PubMed ID: 26469270
[TBL] [Abstract][Full Text] [Related]
17. Fat and Protein Combat Triggers Immunological Weapons of Innate and Adaptive Immune Systems to Launch Neuroinflammation in Parkinson's Disease.
Hatton SL; Pandey MK
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163013
[TBL] [Abstract][Full Text] [Related]
18. Distinct Effects of Familial Parkinson's Disease-Associated Mutations on α-Synuclein Phase Separation and Amyloid Aggregation.
Xu B; Fan F; Liu Y; Liu Y; Zhou L; Yu H
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238596
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease.
Kasen A; Houck C; Burmeister AR; Sha Q; Brundin L; Brundin P
Neurobiol Dis; 2022 May; 166():105654. PubMed ID: 35143968
[TBL] [Abstract][Full Text] [Related]
20. The Interplay between Alpha-Synuclein Clearance and Spreading.
Lopes da Fonseca T; Villar-Piqué A; Outeiro TF
Biomolecules; 2015 Apr; 5(2):435-71. PubMed ID: 25874605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
